ChemoCentryx (CCXI) Gets a Buy Rating from Raymond James
In a report released today, Steven Seedhouse from Raymond James reiterated a Buy rating on ChemoCentryx (CCXI), with a price target of $102.00. The company’s shares closed last Tuesday at $58.96.
According to TipRanks.com, Seedhouse is a 5-star analyst with an average return of 16.8% and a 50.8% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ChemoCentryx with a $69.17 average price target, a 20.4% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $54.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.49 and a one-year low of $6.16. Currently, ChemoCentryx has an average volume of 633.6K.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.